PURPOSE: Patients with metastatic breast cancer (MBC) refractory to standard therapy have a poor prognosis. We assessed prognostic factors and clinical outcomes for patients with MBC referred to a phase I clinic focused primarily on targeted agents. PATIENTS AND METHODS: We reviewed the medical records of sequential patients with MBC who presented to our phase I clinic between September 2004 and May 2008 to assess baseline patient characteristics, overall survival (OS), and clinical benefit. RESULTS: A total of 92 patients were identified, with a median age of 53 years (range, 28-83 years). The median number of previous therapies was 5 (range, 1-16 therapies). Of 92 patients, 78 were eligible for and offered > or = 1 phase I clinical trial. With a median follow-up of 7.4 months, the median OS was 6.7 months (95% CI, 5.2-9.7). In multivariate analysis, independent factors predicting shorter survival were > or = 10 previous treatments (vs. < 10 previous treatments; hazard ratio [HR], 3.27; 95% CI, 1.37-7.81; P = .008), Eastern Cooperative Oncology Group (ECOG) performance status (PS) 2/3 (vs. 0/1; HR, 2.92; 95% CI, 1.28-6.66; P = .01), and albumin level < 3.5 g/dL (vs. > 3.5 g/dL; HR, 2.88; 95% CI, 1.41-5.89; P = .004). CONCLUSION: Patients with locally advanced or metastatic breast cancer referred for our phase I studies had a median survival of 6.7 months. Heavily pretreated disease, poor ECOG PS, and/or low albumin levels were associated with significantly shorter survival in a multivariate analysis.
PURPOSE:Patients with metastatic breast cancer (MBC) refractory to standard therapy have a poor prognosis. We assessed prognostic factors and clinical outcomes for patients with MBC referred to a phase I clinic focused primarily on targeted agents. PATIENTS AND METHODS: We reviewed the medical records of sequential patients with MBC who presented to our phase I clinic between September 2004 and May 2008 to assess baseline patient characteristics, overall survival (OS), and clinical benefit. RESULTS: A total of 92 patients were identified, with a median age of 53 years (range, 28-83 years). The median number of previous therapies was 5 (range, 1-16 therapies). Of 92 patients, 78 were eligible for and offered > or = 1 phase I clinical trial. With a median follow-up of 7.4 months, the median OS was 6.7 months (95% CI, 5.2-9.7). In multivariate analysis, independent factors predicting shorter survival were > or = 10 previous treatments (vs. < 10 previous treatments; hazard ratio [HR], 3.27; 95% CI, 1.37-7.81; P = .008), Eastern Cooperative Oncology Group (ECOG) performance status (PS) 2/3 (vs. 0/1; HR, 2.92; 95% CI, 1.28-6.66; P = .01), and albumin level < 3.5 g/dL (vs. > 3.5 g/dL; HR, 2.88; 95% CI, 1.41-5.89; P = .004). CONCLUSION:Patients with locally advanced or metastatic breast cancer referred for our phase I studies had a median survival of 6.7 months. Heavily pretreated disease, poor ECOG PS, and/or low albumin levels were associated with significantly shorter survival in a multivariate analysis.
Authors: A Schwandt; P J Harris; S Hunsberger; A Deleporte; G L Smith; D Vulih; B D Anderson; S P Ivy Journal: Clin Cancer Res Date: 2014-07-15 Impact factor: 12.531
Authors: A T Brunetto; D Sarker; D Papadatos-Pastos; R Fehrmann; S B Kaye; S Johnston; M Allen; J S De Bono; C Swanton Journal: Br J Cancer Date: 2010-07-27 Impact factor: 7.640
Authors: Filipa Lynce; Matthew J Blackburn; Ling Cai; Heping Wang; Larry Rubinstein; Pamela Harris; Claudine Isaacs; Paula R Pohlmann Journal: Breast Cancer Res Treat Date: 2017-11-08 Impact factor: 4.872
Authors: Bradley R Corr; Marisa Moroney; Jeanelle Sheeder; S Gail Eckhardt; Brandon Sawyer; Kian Behbakht; Jennifer R Diamond Journal: Cancer Date: 2020-07-22 Impact factor: 6.860
Authors: Jennifer J Wheler; Barbara A Parker; Jack J Lee; Johnique T Atkins; Filip Janku; Apostolia M Tsimberidou; Ralph Zinner; Vivek Subbiah; Siqing Fu; Richard Schwab; Stacy Moulder; Vicente Valero; Maria Schwaederle; Roman Yelensky; Vincent A Miller; M Philip J Stephens; Funda Meric-Bernstam; Razelle Kurzrock Journal: Oncotarget Date: 2014-05-15